Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 5 of the 28 sources its claims cite were checked for support.
Abstract
De novo mutations affect risk for many diseases and disorders, especially those with early-onset. An example is autism spectrum disorders (ASD). Four recent whole-exome sequencing (WES) studies of ASD families revealed a handful of novel risk genes, based on independent de novo loss-of-function (LoF) mutations falling in the same gene, and found that de novo LoF mutations occurred at a twofold higher rate than expected by chance. However successful these studies were, they used only a small fraction of the data, excluding other types of de novo mutations and inherited rare variants. Moreover, such analyses cannot readily incorporate data from case-control studies. An important research challenge in gene discovery, therefore, is to develop statistical methods that accommodate a broader class of rare variation. We develop methods that can incorporate WES data regarding de novo mutations, inherited variants present, and variants identified within cases and controls. TADA, for Transmission And De novo Association, integrates these data by a gene-based likelihood model involving parameters for allele frequencies and gene-specific penetrances. Inference is based on a Hierarchical Bayes strategy that borrows information across all genes to infer parameters that would be difficult to estimate for individual genes. In addition to theoretical development we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis. Thus TADA's integration of various kinds of WES data can be a highly effective means of identifying novel risk genes. Indeed, application of TADA to WES data from subjects with ASD and their families, as well as from a study of ASD subjects and controls, revealed several novel and promising ASD candidate genes with strong statistical support.
Overview
CoChat Summary
TL;DR
TADA is a hierarchical Bayesian gene-based method that integrates de novo, inherited transmitted/nontransmitted, and case-control rare variant data to identify disease risk genes. Applied to autism spectrum disorder exome data, it estimates about 1,000 ASD risk genes with average loss-of-function relative risk about 20 and identifies novel candidate genes with greater power than de novo-only or meta-analytic tests.
Key findings
- In simulations, TADA had superior power: for a gene with typical parameter values at type I error 0.001, its power was about fivefold larger than the De Novo and Meta tests; genome-wide at FDR below 10%, TADA identified more than 200 ASD risk genes, versus about 50 for the De Novo test and about 70 for the Meta test.
- Using the model, the authors estimated approximately 1,000 ASD risk genes with an average relative risk of approximately 20 due to LoF mutations; an earlier multi-hit-count analysis gave a plausible range of 550 to 1000 risk genes.
- De novo LoF mutations occurred at about a twofold higher rate in ASD probands than unaffected siblings; de novo probably damaging missense (Mis3) mutations were also higher in probands but less strikingly, while other mutation types showed essentially no difference.
- Applying TADA to combined ASD data, 15 genes met an FDR less than 20%, including all five genes with two de novo LoF mutations and novel candidates such as KATNAL2, CHD8, S100G, DYRK1A, PPM1D, SCN2A, CUL3, DEAF1, BANK1, POGZ, WDR55, FAM91A1, and COL25A1.
Methods
- TADA uses a gene-based likelihood model for rare deleterious mutations acting dominantly, with parameters for mutation rate, allele frequency, and gene-specific relative risk/penetrance; it tests relative risk equal to 1 versus greater than 1 using a Hierarchical Bayes/Empirical Bayes strategy that borrows information across genes and can combine multiple mutation types.
- Data included de novo mutations from 932 ASD families across four whole-exome sequencing studies, transmitted/nontransmitted variants from 641 of those families, and case-control data from the ARRA Autism Sequencing Consortium consisting of 935 ASD subjects and 870 controls; analyses focused on LoF and PolyPhen2 “probably damaging” (Mis3) mutations.
- The authors performed simulations under null and alternative models using estimated ASD genetic parameters, applied TADA to ASD data with Benjamini-Hochberg FDR control, and conducted sensitivity analyses varying mutation rates and the prior average relative risk.
Limitations
- The paper states that genotyping/sequencing errors can bias family and combined data analyses, though it argues the variant calls were carefully validated and harmonized; modeling measurement errors is left for future research. It also notes TADA is a one-sided test powered to detect over-transmitted risk variants, so under-transmission bias is not a major concern.
- The paper cautions that the S100G signal is based on a splice variant common in African populations and should be viewed with caution, and that a C1orf95 signal is likely due to population substructure.
- Evident in the text: the method relies on PolyPhen2 classification and downweighting of missense mutations, and the top-gene list uses an FDR threshold of less than 20%, which is relatively permissive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
4 Valid · 7 Not valid · 19 Not checked · 80 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] (see Text S1).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Introduction states that for these data 'population structure appears to be corrected for by using principal components analysis'. In Results > Distribution of AASC Data the paper defines exactly the modified genomic control factor the citing sentence points to — lambda-1, 'a variant on the GC principle based on the first quantile (rather than the median) of the p-value distribution', which 'has an expected value of 1 when there is no confounding due to population structure (see Text S1)' — and reports that the observed lambda-1 'is close to the mean of the simulated distribution for all 3 choices of eigen-vectors', that it is 'controlled fairly well in the Baylor and Broad samples individually' with only 'a slight inflation (1.08)' in mega SKAT, and that the test statistics 'follow the null hypothesis quite closely'. The residual elevation of the standard median-based GC factor is explicitly attributed to SKAT p-values biased toward .5, 'an apparent, but uninteresting inflation', not to stratification — so the substance of 'negligible overall inflation from population stratification' is stated here, with the paper's own hedge ('slight inflation' in mega-analysis) being the mildest qualification. (LLM, conf=0.82)
- Not checked yetcites [10] B Devlin, 1999, Genomic control for association studies, Biometrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“This allele is common in African populations [40].”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Analysis of data to identify genes affecting the risk of ASD
What the sources say
- Could not verifycites [40] JA Tennessen, 2012, Evolution and functional impact of rare coding variation from deep sequencing of human exomes, Science sourceExperimental — accuracy not yet measured
Our copy of Tennessen et al. (2012) never mentions C1orf95: searches for 'C1orf95', for a variant common/high-frequency in African populations, and for the candidate-gene lists (Impact of natural selection on rare coding variation; Patterns of coding variation by gene and pathway) returned only genome-wide summaries, with named loci limited to HLA, DEFB108B, olfactory receptors and histone genes. The paper reports general population-frequency patterns — 86% of >500,000 SNVs rare (MAF <0.5%), 82% population-specific, and higher diversity in AAs (Abstract; Data generation and variant discovery) — but makes no locus-specific statement about a C1orf95 allele. Nothing in our copy contradicts the claim either, so it cannot be settled from this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“the case-control data have been carefully harmonized to minimize batch effects by using stringent quality control filters [7]”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Discussion
What the sources say
- Supportedcites [7] L Liu, 2013, Analysis of Rare, Exonic Variation amongst Subjects with Autism Spectrum Disorders and Population Controls, PLoS Genet source
The Results section, “Harmonizing Calls of Genotype across Sequencing Platforms,” describes increasingly stringent filters used to make the case-control datasets more similar. The Discussion says the authors constructed additional filters to reduce differences in rare-variant distributions between sequencing centers, while cautioning that some heterogeneity could remain after filtering. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting risk for ASD and show it has dramatically better power than other common methods of analysis.”
- Also stated in: § Power analysis by simulation · plain
“This comprehensive simulation showed TADA has superior power relative to the other two tests (Figure S3).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Power analysis by simulation · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“matching the expected with the observed value of , we estimate the the number of ASD risk genes is between 550 to 1000 (Figure 3B).”
§ Integrated Model of De Novo and Inherited Genetic Variants Yields Greater Power to Identify Risk Genes > Results > Genetic architecture of ASD
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
52 more claims
Create a free account to see all 110 claims and to verify the 23 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“TADA genes were defined as a set of 113 ASD genes that were associated with ASD at an FDR < 0.05.”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We applied a rare-variant transmission and de novo association (TADA) test33 to the combined data in this study to define a set of 125 ASD susceptibility (TADA genes) with FDR < 0.05”
From A phenotypic spectrum of autism is attributable to the combined effects of rare variants, polygenic risk and sex (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, the discovery of less penetrant disorders can be empowered by analytical methodologies that integrate both DNMs and rare inherited variants, such as TADA34.”
From Evidence for 28 genetic disorders discovered by combining healthcare and research data (2020) · cites this paper as [34]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“We control for the multiple hypothesis testing using the Benjamini-Hochberg procedure [11].”
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 5×
“The missense labels are based on predictions from PolyPhen2.”
InfluentialGenomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162 · cited 1×
“The overall inflation of the results due to population stratification is negligible: a modified [7] genomic control factor [10] lq~1:02 (see Text S1).”
Self-citationVisscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.029 · Cited by 2,425 · cited 1×
“It has proven successful for identifying common variation affecting risk, after sufficient samples had been amassed to ensure variation having modest impact on risk could be detected [12].”
Tackling the widespread and critical impact of batch effects in high-throughput data
Leek, J. T., Scharpf, R. B., Bravo, H. C., Simcha, D., Langmead, B., Johnson, W. E., Geman, D., Baggerly, K., & Irizarry, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2825 · Cited by 2,196 · cited 1×
“Genotyping/sequencing errors can introduce biases in data analyses, especially those for family data [37,38] and for combining data across multiple heterogeneous studies [39].”
Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations
O’Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., Levy, R., Ko, A., Lee, C., Smith, J. D., et al. (2012) · Nature · doi:10.1038/nature10989 · Cited by 2,165 · cited 7×
“Consider the de novo LoF mutations in N~932 families [1–4].”
InfluentialRate of de novo mutations and the importance of father’s age to disease risk
Kong, A., Frigge, M. L., Masson, G., Besenbacher, S., Sulem, P., Magnusson, G., Gudjonsson, S. A., Sigurdsson, A., Jonasdottir, A., Jonasdottir, A., et al. (2012) · Nature · doi:10.1038/nature11396 · Cited by 2,134 · cited 1×
“A recent study identified an additional de novo protein-changing mutation in CUL3 in ASD probands [27], replicating our finding here.”
De novo mutations revealed by whole-exome sequencing are strongly associated with autism
Sanders, S. J., Murtha, M. T., Gupta, A. R., Murdoch, J. D., Raubeson, M. J., Willsey, A. J., Ercan-Sencicek, A. G., DiLullo, N. M., Parikshak, N. N., Stein, J. L., et al. (2012) · Nature · doi:10.1038/nature10945 · Cited by 2,084 · cited 7×
“For each gene, the total rate of base pair substitutions was estimated using a probability model taking the gene length and base content into account [1].”
InfluentialSelf-citationFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013 · cited 1×
“Indeed virtually every discovery for ASD risk genes traces to rare and de novo variants [1–4,16–20].”
Patterns and rates of exonic de novo mutations in autism spectrum disorders
Neale, B. M., Kou, Y., Liu, L., Ma’ayan, A., Samocha, K. E., Sabo, A., Lin, C.-F., Stevens, C., Wang, L.-S., Makarov, V., et al. (2012) · Nature · doi:10.1038/nature11011 · Cited by 1,734 · cited 3×
“Based on computations of expected rates of de novo events as a function of a gene’s exonic length and base pair composition [2], a recent study [1] found that d§2 LoF events for Nv1000 is significant evidence to declare a gene as a risk gene (pv0:05, genomewide).”
Self-citation
Cited by
Synaptic, transcriptional and chromatin genes disrupted in autism
Study, T. D., De Rubeis, S., Autism, H. M. C. F., UK10K Consortium, The Autism Sequencing Consortium, He, X., Goldberg, A. P., Poultney, C. S., Samocha, K., Ercument Cicek, A., et al. (2014) · Nature · doi:10.1038/nature13772 · Cited by 2,746
“For de novo LoF and Mis3 mutations, we have estimated their average RRs in He et al. (2013), and the value for the LoF mutations is about 20 and that of the Mis3 mutations is about 4.”
Self-citationSatterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J.-Y., Peng, M., Collins, R., Grove, J., Klei, L., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.036 · Cited by 2,321
“Effect of Genetic Variants on ASD Risk Because protein-truncating variants (PTVs; nonsense, frameshift, and essential splice site variants) show a greater difference in burden between ASD cases and controls than missense variants, their average effect on liability must be larger (He et al., 2013).”
BackgroundMethodInfluentialSelf-citationLord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Self-citationInsights into autism spectrum disorder genomic architecture and biology from 71 risk loci
Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., Samocha, K. E., Cicek, A. E., Murtha, M. T., Bal, V. H., Bishop, S. L., Dong, S., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.09.016 · Cited by 1,430
“Second, many large CNVs contain sufficient numbers of genes that numerous ASD risk genes would be expected based solely on the fact that 800 genes are likely contributing to ASD risk (He et al., 2013; Sanders et al., 2012).”
BackgroundMethodInfluentialSelf-citationRare-Variant Association Analysis: Study Designs and Statistical Tests
Lee, S., Abecasis, G. R., Boehnke, M., & Lin, X. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.06.009 · Cited by 1,042
“131 In addition to the frequentist approaches we have primarily covered in this paper, Bayesian methods can provide an alternative framework for evaluating rare-variant association.”
MethodWillsey, A. J., Sanders, S. J., Li, M., Dong, S., Tebbenkamp, A. T., Muhle, R. A., Reilly, S. K., Lin, L., Fertuzinhos, S., Miller, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.020 · Cited by 934
“Although de novo point mutations have so far been estimated to play a contributory role in approximately 15% of affected individuals, estimates of locus heterogeneity imparted by these mutations alone already range from several hundred to more than 1,000 genes (He et al., 2013; Iossifov et al., 2012; Sanders et al., 2…”
InfluentialSelf-citationAn Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options
Masi, A., DeMayo, M. M., Glozier, N., & Guastella, A. J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0100-y · Cited by 987
“It is estimated that 400–1000 genes are likely to lead to a susceptibility to autism [37, 38].”
BackgroundFu, J. M., Satterstrom, F. K., Peng, M., Brand, H., Collins, R. L., Dong, S., Wamsley, B., Klei, L., Wang, L., Hao, S. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01104-0 · Cited by 640
Self-citationEvidence for 28 genetic disorders discovered by combining healthcare and research data
Kaplanis, J., Samocha, K. E., Wiel, L., Zhang, Z., Arvai, K. J., Eberhardt, R. Y., Gallone, G., Lelieveld, S. H., Martin, H. C., McRae, J. F., et al. (2020) · Nature · doi:10.1038/s41586-020-2832-5 · Cited by 615
Statistical power and significance testing in large-scale genetic studies
Sham, P. C., & Purcell, S. M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3706 · Cited by 573
Gene hunting in autism spectrum disorder: on the path to precision medicine
Geschwind, D. H., & State, M. W. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00044-7 · Cited by 471
Self-citationInherited and de novo genetic risk for autism impacts shared networks
Ruzzo, E. K., Pérez-Cano, L., Jung, J.-Y., Wang, L.-K., Kashef-Haghighi, D., Hartl, C., Singh, C., Xu, J., Hoekstra, J. N., Leventhal, O., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.015 · Cited by 457
“TADA simulations The distribution of the TADA statistic (under the null) is known for independent trios (He et al., 2013), but not for multiplex families.”
BackgroundMethodInfluentialZhou, X., Feliciano, P., Shu, C., Wang, T., Astrovskaya, I., Hall, J. B., Obiajulu, J. U., Wright, J. R., Murali, S. C., Xu, S. X., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01148-2 · Cited by 453
Self-citationStudy, S. S., Singh, T., Study, I., Study, D., UK10 K Consortium, Kurki, M. I., Curtis, D., Purcell, S. M., Crooks, L., McRae, J., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4267 · Cited by 452
Self-citationStudy, T. I., Sifrim, A., the UK10K Consortium, Study, T. D. D. D., Hitz, M.-P., Wilsdon, A., Breckpot, J., Turki, S. H. A., Thienpont, B., McRae, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3627 · Cited by 449
Krishnan, A., Zhang, R., Yao, V., Theesfeld, C. L., Wong, A. K., Tadych, A., Volfovsky, N., Packer, A., Lash, A., & Troyanskaya, O. G. (2016) · Nature Neuroscience · doi:10.1038/nn.4353 · Cited by 438
Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity
Coe, B. P., Stessman, H. A. F., Sulovari, A., Geisheker, M. R., Bakken, T. E., Lake, A. M., Dougherty, J. D., Lein, E. S., Hormozdiari, F., Bernier, R. A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0288-4 · Cited by 330
Cotney, J., Muhle, R. A., Sanders, S. J., Liu, L., Willsey, A. J., Niu, W., Liu, W., Klei, L., Lei, J., Yin, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7404 · Cited by 350
“Using a new approach called DAWN, Liu et al. 2014 model two kinds of data: rare variations from exome sequencing 41 and gene co-expression in the mid-fetal prefrontal and motor-somatosensory neocortex, a critical nexus for risk 13 .”
Self-citationThe promises and challenges of human brain organoids as models of neuropsychiatric disease
Quadrato, G., Brown, J., & Arlotta, P. (2016) · Nature Medicine · doi:10.1038/nm.4214 · Cited by 304
Getting to the cores of autism
Iakoucheva, L. M., Muotri, A. R., & Sebat, J. (2019) · Cell · doi:10.1016/j.cell.2019.07.037 · Cited by 260
Genomic architecture of autism from comprehensive whole-genome sequence annotation
Trost, B., Thiruvahindrapuram, B., Chan, A. J. S., Engchuan, W., Higginbotham, E. J., Howe, J. L., Loureiro, L. O., Reuter, M. S., Roshandel, D., Whitney, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.009 · Cited by 270
“Discovery of ASD-associated genes Previously, the Autism Sequencing Consortium (ASC) developed TADA+, an enhanced version of the transmission and de novo association (TADA) test (He et al., 2013), and applied it to whole-exome sequencing (WES) data from 6,430 trios, 5,556 cases, and 8,809 controls, identifying 102 ASD…”
BackgroundThe discovery of integrated gene networks for autism and related disorders
Hormozdiari, F., Penn, O., Borenstein, E., & Eichler, E. E. (2015) · Genome Research · doi:10.1101/gr.178855.114 · Cited by 249
“2014) also employs WGCNA as part of a hidden Markov random field algorithm in order to predict risk ASD genes based on TADA scores (He et al. 2013).”
MethodExome sequencing of 457 autism families recruited online provides evidence for autism risk genes
Feliciano, P., Zhou, X., Astrovskaya, I., Turner, T. N., Wang, T., Brueggeman, L., Barnard, R., Hsieh, A., Snyder, L. G., Muzny, D. M., et al. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0093-8 · Cited by 247
Self-citationGenome-wide characteristics of de novo mutations in autism
Yuen, R. K., Merico, D., Cao, H., Pellecchia, G., Alipanahi, B., Thiruvahindrapuram, B., Tong, X., Sun, Y., Cao, D., Zhang, T., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.27 · Cited by 216
Genomics, convergent neuroscience and progress in understanding autism spectrum disorder
Willsey, H. R., Willsey, A. J., Wang, B., & State, M. W. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00576-7 · Cited by 229
Self-citationGenetics and genomics of autism spectrum disorder: embracing complexity
De Rubeis, S., & Buxbaum, J. D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv273 · Cited by 208
“Simulations based on the observed number of recurrently disrupted genes have estimated that there are some 600–1200 ASD risk genes (21,24,26,51).”
BackgroundSelf-citationLoss-of-Function Variants in Schizophrenia Risk and SETD1A as a Candidate Susceptibility Gene
Takata, A., Xu, B., Ionita-Laza, I., Roos, J. L., Gogos, J. A., & Karayiorgou, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.043 · Cited by 204
“To calculate a specific local mutation rate, we used TADA software (He et al., 2013) with default parameters, which estimates the mutation rate per gene based on its exonic length and its nucleotide content (Sanders et al., 2012).”
Li, J., Cai, T., Jiang, Y., Chen, H., He, X., Chen, C., Li, X., Shao, Q., Ran, X., Li, Z., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.40 · Cited by 210
Self-citationAntaki, D., Guevara, J., Maihofer, A. X., Klein, M., Gujral, M., Grove, J., Carey, C. E., Hong, O., Arranz, M. J., Hervas, A., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01064-5 · Cited by 206
Zhang, Y., Lu, Q., Ye, Y., Huang, K., Liu, W., Wu, Y., Zhong, X., Li, B., Yu, Z., Travers, B. G., et al. (2021) · Genome Biology · doi:10.1186/s13059-021-02478-w · Cited by 201
MVP predicts the pathogenicity of missense variants by deep learning
Qi, H., Zhang, H., Zhao, Y., Chen, C., Long, J. J., Chung, W. K., Guan, Y., & Shen, Y. (2021) · Nature Communications · doi:10.1038/s41467-020-20847-0 · Cited by 198
De Novo Coding Variants Are Strongly Associated with Tourette Disorder
Willsey, A. J., Fernandez, T. V., Yu, D., King, R. A., Dietrich, A., Xing, J., Sanders, S. J., Mandell, J. D., Huang, A. Y., Richer, P., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.024 · Cited by 187
Self-citationZhang, Y., Li, N., Li, C., Zhang, Z., Teng, H., Wang, Y., Zhao, T., Shi, L., Zhang, K., Xia, K., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0699-8 · Cited by 177
Takata, A., Miyake, N., Tsurusaki, Y., Fukai, R., Miyatake, S., Koshimizu, E., Kushima, I., Okada, T., Morikawa, M., Uno, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.074 · Cited by 172
Autism spectrum disorders: from genes to neurobiology
Jeremy Willsey, A., & State, M. W. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.10.015 · Cited by 145
“The yield of well-associated genes can be further increased by incorporating de novo missense mutations, inherited mutations, case-control data, and per-gene estimates of mutability [39 ,43], as well as gene expression data from the human brain [39 ,44 ].”
BackgroundSelf-citationPrioritization of neurodevelopmental disease genes by discovery of new mutations
Hoischen, A., Krumm, N., & Eichler, E. E. (2014) · Nature Neuroscience · doi:10.1038/nn.3703 · Cited by 149
Autism Spectrum Disorder Genetics and the Search for Pathological Mechanisms
Manoli, D. S., & State, M. W. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111608 · Cited by 146
Self-citationNeocortical neurogenesis and the etiology of autism spectrum disorder
Packer, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.002 · Cited by 138
Recent ultra-rare inherited variants implicate new autism candidate risk genes
Wilfert, A. B., Turner, T. N., Murali, S. C., Hsieh, P., Sulovari, A., Wang, T., Coe, B. P., Guo, H., Hoekzema, K., Bakken, T. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00899-8 · Cited by 136
Kuechler, A., Zink, A. M., Wieland, T., Lüdecke, H.-J., Cremer, K., Salviati, L., Magini, P., Najafi, K., Zweier, C., Czeschik, J. C., et al. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.165 · Cited by 151
DAWN: a framework to identify autism genes and subnetworks using gene expression and genetics
Liu, L., Lei, J., Sanders, S. J., Willsey, A. J., Kou, Y., Cicek, A. E., Klei, L., Lu, C., He, X., Li, M., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-22 · Cited by 133
“Our recent work estimates this number to be about 1,000 [1,9,12], a remarkably high fraction of the known genes in the genome.”
BackgroundMethodResultInfluentialSelf-citationWillsey, A. J., Morris, M. T., Wang, S., Willsey, H. R., Sun, N., Teerikorpi, N., Baum, T. B., Cagney, G., Bender, K. J., Desai, T. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.016 · Cited by 128
“We considered de novo variant FDRs (He et al., 2013).”
Self-citationSestan, N., & State, M. W. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.015 · Cited by 127
Self-citationWang, S., Mandell, J. D., Kumar, Y., Sun, N., Morris, M. T., Arbelaez, J., Nasello, C., Dong, S., Duhn, C., Zhao, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.082 · Cited by 126
“Integrated Analysis Identifies Additional TD Risk Genes, Including a High-Confidence Gene CELSR3 We leveraged de novo damaging variants and the Transmission and De Novo Association (TADA) algorithm to estimate pergene association with TD (De Rubeis et al., 2014; He et al., 2013; Sanders et al., 2015; Willsey et al., 2…”
Self-citationA framework for the investigation of rare genetic disorders in neuropsychiatry
Sanders, S. J., Sahin, M., Hostyk, J., Thurm, A., Jacquemont, S., Avillach, P., Douard, E., Martin, C. L., Modi, M. E., Moreno-De-Luca, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0581-5 · Cited by 123
Self-citationThe contributions of rare inherited and polygenic risk to ASD in multiplex families
Cirnigliaro, M., Chang, T. S., Arteaga, S. A., Pérez‐Cano, L., Ruzzo, E. K., Gordon, A., Bicks, L. K., Jung, J.-Y., Lowe, J. K., Wall, D. P., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215632120 · Cited by 151
“In order to combine evidence found in ASD cases from rare de novo (DN) or transmitted (inherited) PTVs as well as de novo Mis3 variants predicted to damage the encoded protein, we used the Transmitted and De novo Association (TADA) test (He et al., 2013).”
Biomarkers in autism spectrum disorders: Current progress
Shen, L., Liu, X., Zhang, H., Lin, J., Feng, C., & Iqbal, J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.009 · Cited by 121
Human cerebellar organoids with functional Purkinje cells
Atamian, A., Birtele, M., Hosseini, N., Nguyen, T. N., Seth, A., Dosso, A. D., Paul, S., Tedeschi, N., Taylor, R., Coba, M. P., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2023.11.013 · Cited by 129
Gazestani, V., Pramparo, T., Nalabolu, S. R., Kellman, B. P., Murray, S. S., Lopez, L., Pierce, K., Courchesne, E., & Lewis, N. E. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0489-x · Cited by 126
Mutations and Modeling of the Chromatin Remodeler CHD8 Define an Emerging Autism Etiology
Barnard, R. A., Pomaville, M. B., & O'Roak, B. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00477 · Cited by 107
Cappi, C., Oliphant, M. E., Péter, Z., Zai, G., Conceição do Rosário, M., Sullivan, C. A. W., Gupta, A. R., Hoffman, E. J., Virdee, M., Olfson, E., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.029 · Cited by 106
“We used the Transmitted And De novo Association (TADA) test as a statistical method for risk gene discovery based on gene-level recurrence of de novo and inherited mutations within the classes of variants that we found enriched in OCD (29, 40).”
MethodLi, J., Wang, L., Guo, H., Shi, L., Zhang, K., Tang, M., Hu, S., Dong, S., Liu, Y., Wang, T., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.140 · Cited by 103
Self-citationPredicting functional effect of missense variants using graph attention neural networks
Zhang, H., Xu, M. S., Fan, X., Chung, W. K., & Shen, Y. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00561-w · Cited by 98
Willsey, H. R., Exner, C. R. T., Xu, Y., Everitt, A., Sun, N., Wang, B., Dea, J., Schmunk, G., Zaltsman, Y., Teerikorpi, N., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.01.002 · Cited by 96
Self-citationThe Genetics of Autism Spectrum Disorders
Huguet, G., Benabou, M., & Bourgeron, T. (2016) · Research and perspectives in endocrine interactions · doi:10.1007/978-3-319-27069-2_11 · Cited by 125
Nguyen, H. T., Bryois, J., Kim, A., Dobbyn, A., Huckins, L. M., Munoz-Manchado, A. B., Ruderfer, D. M., Genovese, G., Fromer, M., Xu, X., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0497-y · Cited by 91
“We developed an improved hierarchical Bayesian modeling framework [16], Extended Transmission and de novo Association (extTADA), to analyze whole exome sequence data in SCZ and four NDDs (ASD, ID, DD, and EPI), which have substantial clinical and etiological overlap.”
BackgroundMethodInfluentialSelf-citationFirst glimpses of the neurobiology of autism spectrum disorder
Sanders, S. J. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.10.002 · Cited by 84
Self-citationBayesian estimation of gene constraint from an evolutionary model with gene features
Zeng, T., Spence, J. P., Mostafavi, H., & Pritchard, J. K. (2024) · Nature Genetics · doi:10.1038/s41588-024-01820-9 · Cited by 81
“For example, GeneBayes can be used to find trait-associated genes using variants from case/control studies [70, 71], or to improve power to find differentially expressed genes in RNA-seq experiments [72].”
Genetic architecture of autism spectrum disorder: Lessons from large-scale genomic studies
Choi, L., & An, J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.028 · Cited by 87
“Later, a novel statistical method called the Transmitted And De novo Association (TADA) test (He et al., 2013) was developed for ASD gene”
InfluentialDou, Y., Yang, X., Li, Z., Wang, S., Zhang, Z., Ye, A. Y., Yan, L., Yang, C., Wu, Q., Li, J., et al. (2017) · Human Mutation · doi:10.1002/humu.23255 · Cited by 79
“…de novo loss-offunction (LoF) mutations and de novomissense mutations with deleterious effects, which have been described and calculated previously (He et al., 2013; Sanders et al., 2015); BpSNM is the Bayes factor from functional pSNMswith a highMAF; and Bdenovo_pm is the Bayes factor from de…”
BackgroundMethodInfluentialRecent Advances in the Genetics of Autism Spectrum Disorder
Rubeis, S. D., & Buxbaum, J. D. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0553-1 · Cited by 89
Self-citationThe contribution of copy number variants to psychiatric symptoms and cognitive ability
Mollon, J., Almasy, L. A., Jacquemont, S., & Glahn, D. C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01978-4 · Cited by 87
“Moreover, considering most CNVs associated with risk for neurodevelopmental disorders encompass dozens of genes, recent work has focused on identifying major risk genes [61, 62], although with limited success.”
BackgroundWang, W., Corominas, R., & Lin, G. N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00258 · Cited by 70
“By combining de novo and transmitted variants in its analysis, TADA (He et al., 2013; Sanders et al., 2015) assumes that candidate genes for neuropsychiatric disorders would give different types of risks to the disease.”
BackgroundMethodGenetic heterogeneity in autism: From single gene to a pathway perspective
An, J., & Claudianos, C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.013 · Cited by 76
The contribution of X-linked coding variation to severe developmental disorders
Martin, H. C., Gardner, E. J., Samocha, K. E., Kaplanis, J., Akawi, N. A., Sifrim, A., Eberhardt, R. Y., Tavares, A. L. T., Neville, M. D. C., Niemi, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20852-3 · Cited by 77
Gene4Denovo: an integrated database and analytic platform for de novo mutations in humans
Zhao, G., Li, K., Li, B., Wang, Z., Fang, Z., Wang, X., Zhang, Y., Luo, T., Zhou, Q., Wang, L., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz923 · Cited by 73
“The transmitted and de novo association (TADA) model (72) was used to calculate the P-value and false discovery rate (FDR) for each gene with Pfun variants in each disorder (Supplementary Table S2).”
MethodDe novo missense variants in HECW2 are associated with neurodevelopmental delay and hypotonia
Berko, E. R., Cho, M. T., Eng, C., Shao, Y., Sweetser, D. A., Waxler, J., Robin, N. H., Brewer, F., Donkervoort, S., Mohassel, P., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103943 · Cited by 65
De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and Network Analysis
Alonso-González, A., Rodriguez‐Fontenla, C., & Carracedo, Á. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00406 · Cited by 87
“…differentiated modules of genes during brain development, one expressed from 8–14 weeks post-conception, which includes genes related to the Wnt pathway, and another that contains genes related to synaptic function and that is more strongly expressed in postnatal stages (Hormozdiari et al., 2015).”
BackgroundSatterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J.-Y., Peng, M., Collins, R., Grove, J., Klei, L., et al. (2018) · doi:10.1101/484113 · Cited by 2,323
“For our earlier published work, we used the Transmitted And De novo 6 Association (TADA) model (15) to integrate missense and PTVs that are de novo, inherited, or 7 from case-control populations to stratify autosomal genes by FDR for association (5, 10).”
BackgroundMethodSelf-citationHow rare and common risk variation jointly affect liability for autism spectrum disorder
Klei, L., McClain, L. L., Mahjani, B., Panayidou, K., Rubeis, S. D., Grahnat, A.-C. S., Karlsson, G., Lu, Y., Melhem, N., Xu, X., et al. (2021) · Molecular Autism · doi:10.1186/s13229-021-00466-2 · Cited by 71
“While imperfect, a rough way to account for this confounder is to use the TADA Bayes factor [41], which summarizes the evidence for association from the expected spectrum of PDVs, based on gene size and nucleotide content, to that observed in the sample.”
MethodSelf-citationMillan, F., Cho, M. T., Retterer, K., Monaghan, K. G., Bai, R., Vitazka, P., Everman, D. B., Smith, B. T., Angle, B., Roberts, V., et al. (2016) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37670 · Cited by 68
Joudar, S. S., Albahri, A. S., & Hamid, R. A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105553 · Cited by 76
Cerebral organoids as tools to identify the developmental roots of autism
Chan, W. K., Griffiths, R., Price, D. J., & Mason, J. O. (2020) · Molecular Autism · doi:10.1186/s13229-020-00360-3 · Cited by 62
“It is estimated that as many as 300-1000 genes could be targets for rare mutations which greatly increase the risk of ASD, potentially explaining some idiopathic cases [60, 125].”
BackgroundDiscovery of rare variants for complex phenotypes
Kosmicki, J. A., Churchhouse, C. L., Rivas, M. A., & Neale, B. M. (2016) · Human Genetics · doi:10.1007/s00439-016-1679-1 · Cited by 61
AutismKB 2.0: a knowledgebase for the genetic evidence of autism spectrum disorder
Yang, C., Li, J., Wu, Q., Yang, X., Huang, A. Y., Zhang, J., Ye, A. Y., Dou, Y., Yan, L., Zhou, W., et al. (2018) · Database · doi:10.1093/database/bay106 · Cited by 64
“Thousands of genes have been reported to be associated with ASD (10–13, 48, 49).”
BackgroundLeveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders
Searles, V. B., Wang, B., & State, M. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0768-y · Cited by 56
“More recent statistical developments have included the “transmitted and de novo association” (TADA) method [65, 66] which incorporates information from multiple variant classes, leveraging both the statistical power of rare recurrent de novo germline mutations and the greater frequency of transmitted variants to elega…”
MethodSelf-citationXu, J., Li, Z., Ren, X., Dong, M., Li, J., Shi, X., Zhang, Y. L., Xie, W., Sun, Z. S., Liu, X., et al. (2015) · Scientific Reports · doi:10.1038/srep16609 · Cited by 55
Increased burden of deleterious variants in essential genes in autism spectrum disorder
Ji, X., Kember, R. L., Brown, C. D., & Bućan, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613195113 · Cited by 56
“To further address whether EGs contribute to ASD risk, we compared the strength of ASD association signals between EGs and NEGs in data from a recent comprehensive analysis of ASD genomic architecture (9), where the transmission and de novo association (TADA) test (38) was used to evaluate ASD *** ***”
ResultQiao, L., Xu, L., Yu, L., Wynn, J., Hernan, R., Zhou, X., Farkouh‐Karoleski, C., Krishnan, U., Khlevner, J., De, A., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.08.011 · Cited by 51
Genomic landscapes of Chinese sporadic autism spectrum disorders revealed by whole-genome sequencing
Wu, J., Yu, P., Jin, X., Xu, X., Li, J., Li, Z., Wang, M., Wang, T., Wu, X., Jiang, Y. W., et al. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2018.09.002 · Cited by 50
A systematic variant annotation approach for ranking genes associated with autism spectrum disorders
Larsen, E., Menashe, I., Ziats, M. N., Pereanu, W., Packer, A., & Banerjee-Basu, S. (2016) · Molecular Autism · doi:10.1186/s13229-016-0103-y · Cited by 49
The Yin and Yang of Autism Genetics: How Rare De Novo and Common Variations Affect Liability
Chaste, P., Roeder, K., & Devlin, B. (2017) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022647 · Cited by 61
“(59) have refined this inferential method, creating a Bayesian gene-based likelihood model called Transmission and De Novo Association (TADA) that assesses disease association from the count of de novo mutations, inherited variants, and variants identified within cases and controls.”
MethodSelf-citationJin, Z., Li, Z., Liu, Z., Jiang, Y. W., Cai, X., & Wu, J. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12383 · Cited by 55
“Collectively, both de novo and inherited mutations should be considered for pathogenic mutation identification, as applied in the TADA prioritization tool (He et al., 2013).”
BackgroundMethodInfluentialLi, Q., Zhao, L., Zeng, Y., Kuang, Y., Guan, Y., Chen, B., Xu, S., Tang, B., Wu, L., Mao, X., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02894-0 · Cited by 46
“As a Bayesian model, TADA is useful for evaluating rare variations using whole exome sequencing data [14].”
MethodZhou, W., Zhang, J., Li, Z., Lin, X., Li, J., Wang, S., Yang, C., Wu, Q., Ye, A. Y., Wang, M., et al. (2019) · Human Mutation · doi:10.1002/humu.23724 · Cited by 47
Arpi, M. N. T., & Simpson, T. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-14077-1 · Cited by 58
Han, X., Chen, S., Flynn, E. D., Wu, S., Wintner, D., & Shen, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-04552-7 · Cited by 46
“However, relatively few genes have multiple LGD variants ( “ recurrence ” ) in a cohort 1,2,6 , lacking of which provides insuf-fi cient statistical evidence to distinguish individual risk genes from the ones with random mutations 7 .”
BackgroundDu, Y., Li, Z., Liu, Z., Zhang, N., Wang, R., Li, F., Zhang, T., Jiang, Y., Zhi, X., Wang, Z., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0610-2 · Cited by 45
Deep Genetic Connection Between Cancer and Developmental Disorders: HUMAN MUTATION
Qi, H., Dong, C., Chung, W. K., Wang, K., & Shen, Y. (2016) · Human Mutation · doi:10.1002/humu.23040 · Cited by 39
“To identify a broad set of candidate risk genes of development disorders, we applied TADA [He et al., 2013; De Rubeis et al., 2014], a probabilistic method for identifying risk genes based on de novo or rare variants.”
MethodInfluentialNCKAP1 Disruptive Variants Lead to a Neurodevelopmental Disorder with Core Features of Autism
Guo, H., Zhang, Q., Dai, R., Yu, B., Hoekzema, K., Tan, J., Tan, S., Jia, X., Chung, W. K., Hernan, R., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.10.002 · Cited by 38
“We first assessed an enrichment of de novo LGD variants among probands compared with random occurrence by applying TADA.(14) Six individuals with de novo NCKAP1 LGD variants were detected from four cohorts (SSC: c.”
MethodRare deleterious mutations of the gene EFR3A in autism spectrum disorders
Gupta, A. R., Pirruccello, M., Cheng, F., Kang, H., Fernandez, T. V., Baskin, J. M., Choi, M., Liu, L., Ercan‐Sencicek, A. G., Murdoch, J. D., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-31 · Cited by 38
“However, there is abundant evidence that inherited mutations also contribute to ASD [31].”
BackgroundSelf-citationRare variants and the oligogenic architecture of autism
Wang, T., Zhao, P. A., & Eichler, E. E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.03.009 · Cited by 38
Kaplanis, J., Samocha, K. E., Wiel, L., Zhang, Z., Arvai, K. J., Eberhardt, R. Y., Gallone, G., Lelieveld, S. H., Martin, H. C., McRae, J. F., et al. (2019) · doi:10.1101/797787 · Cited by 36
Tanaka, A. J., Cho, M. T., Willaert, R. K., Retterer, K., Zárate, Y. A., Bosanko, K., Stefans, V., Oishi, K., Williamson, A., Wilson, G. N., et al. (2017) · Molecular Case Studies · doi:10.1101/mcs.a002097 · Cited by 43
“Using TADA (He et al. 2013) default parameters for ID/DD and the expectedmutation rate of 2.331847 × 10−05 for missense variants and 8.693607 × 10−07 for LOF variants (Samocha et al. 2014), we calculate a falsediscovery corrected q-value of 3.84 × 10−08 for observing six de novo LOF and five de novo missense variants…”
MethodInfluentialDe novo FBXO11 mutations are associated with intellectual disability and behavioural anomalies
Fritzen, D., Kuechler, A., Grimmel, M., Becker, J., Peters, S., Sturm, M., Hundertmark, H., Schmidt, A., Kreiß, M., Strom, T. M., et al. (2018) · Human Genetics · doi:10.1007/s00439-018-1892-1 · Cited by 35
Identification of putative causal loci in whole-genome sequencing data via knockoff statistics
He, Z., Liu, L., Wang, C., Guen, Y. L., Lee, J., Gogarten, S. M., Lu, F., Montgomery, S. B., Tang, H., Silverman, E. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22889-4 · Cited by 48
Self-citationSalgado, D., Bellgard, M., Desvignes, J., & Béroud, C. (2016) · Human Mutation · doi:10.1002/humu.23110 · Cited by 43
“This approach revealed a significant power increase for gene discovery, as demonstrated through the studies of exome data of Autism Spectrum Disorder [He et al., 2013] and might be useful in other situations.”
BackgroundBelmadani, M., Jacobson, M., Holmes, N., Phan, M., Nguyen, T. G., Pavlidis, P., & Rogić, S. (2019) · Autism Research · doi:10.1002/aur.2236 · Cited by 33
The Genetics of Neuropsychiatric Diseases: Looking In and Beyond the Exome
Heinzen, E. L., Neale, B. M., Traynelis, S. F., Allen, A. S., & Goldstein, D. B. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-034136 · Cited by 36
“Thus an analysis that combines these sources of information to implicate specific genes seems natural and, in fact, has been shown to result in an increase in power (He et al. 2013).”
BackgroundBuxbaum, J. D., Bolshakova, N., Brownfeld, J. M., Anney, R. J., Bender, P., Bernier, R., Cook, E. H., Coon, H., Cuccaro, M., Freitag, C. M., et al. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-34 · Cited by 33
“Relevant genetic findings can now be made in over 25% of ASD cases, using Fragile X testing, chromosome microarray (CMA) and WES.”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- He, X., Sanders, S. J., Liu, L., De Rubeis, S., Lim, E. T., Sutcliffe, J. S., Schellenberg, G. D., Gibbs, R. A., Daly, M. J., Buxbaum, J. D., State, M. W., Devlin, B., & Roeder, K.
- Affiliations
- Carnegie Mellon University (US)
- Yale University (US)
- Broad Institute (US)
- Vanderbilt University (US)
- University of Pennsylvania (US)
- Baylor College of Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Pittsburgh (US)
- Corresponding author
- Roeder, Kathryn
- ORCID
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-15
- Volume
- 9
- Issue
- 8
- Pages
- e1003671
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC3744441
- OpenAlex
- W2125226755
- Semantic Scholar
- 041f0c3d75072dec83d95d6bbf32c4757308d641
- Cited by
- 304
- References
- 42
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 29 · 2023: 18 · 2022: 23 · 2021: 31 · 2020: 25 · 2019: 24 · 2018: 26 · 2017: 23 · 2016: 27 · 2015: 21 · 2014: 15 · 2013: 1
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- Autism Speaks
- Simons Foundation
- Simons Foundation Autism Research Initiative
- National Institutes of Health (MH057881)
- National Institute of Mental Health (U01MH100209, R01MH061009, R01MH089025, U01MH100229, MH089004, MH089025, R01MH089175, R01MH089004, R37MH057881, R01MH089208, U01MH100239, R01MH057881, MH089482, MH057881, R01MH089482, MH061009, U01MH100233)
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Keywords
- de novo mutations, autism spectrum disorder, TADA, Bayesian hierarchical model, penetrance, allele frequency, exome sequencing
- MeSH terms
- Bayes Theorem, Child Development Disorders, Pervasive, Humans, Models, Theoretical, Mutation, Risk Factors, Genetic Variation, Likelihood Functions, Case-Control Studies, Sequence Analysis, DNA, Genetic Predisposition to Disease, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.